Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-000280-24 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This single-center, randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. Volunteers will receive multiple-ascending doses of RO5508887 or matching placebo. The anticipated time on study treatment is 14 days.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| RO5508887 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Multiple doses of placebo |
| |
| RO5508887 |
| Measure | Description | Time Frame |
|---|---|---|
| Safety: incidence of adverse events | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of the age on pharmacokinetics of RO5508887 | 30 days | |
| Correlation of the age on pharmacodynamics of RO5508887 | 30 days | |
| Pharmacokinetics: plasma levels of RO5508887 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Strasbourg | 67064 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Multiple doses of RO5508887 |
|
| Predose and up to 144 hours post last dose, and at follow-up |
| Pharmacodynamics: Plasma levels of amyloid deposition markers | Predose and up to 144 hours post last dose |
| Correlation of the age on safety of RO5508887 | 30 days |